A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

Phase 2 Not yet recruiting 23 enrolled Fujian Cancer Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic biliary tract cancer.

Timeline

Start: 2025-01
Primary completion: 2026-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	100 mg/m2	Intravenous
Subject	Surufatinib	Small molecule	200 mg	—
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous

A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

Summary

Timeline

Drugs

Indications